Advanced in Developmental Dysphasia Familial

Stefan Kloppel

Bern, BE, CH 
Advanced in Developmental Dysphasia Familial
Bern, BE, CH 
OverviewLocationsClinical Research

Overview

Stefan Kloppel practices in Bern, Switzerland. Mr. Kloppel is rated as an Advanced expert by MediFind in the treatment of Developmental Dysphasia Familial. His top areas of expertise are Dementia, Alzheimer's Disease, Huntington Disease, and Memory Loss.

His clinical research consists of co-authoring 188 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 10 articles in the study of Developmental Dysphasia Familial.

Gender
Male

Locations

Bern, BE, Switzerland
Other Locations
Switzerland
Brain
Fribourg, FR, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment
Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment
Enrollment Status: Completed
Publish Date: March 13, 2020
Intervention Type: Device
Study Phase: Not Applicable
Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients
Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients
Enrollment Status: Unknown
Publish Date: January 27, 2020
Intervention Type: Drug
Study Drug: Simvastatin
Study Phase: Phase 4
View 1 Less Clinical Trial

188 Total Publications

Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.
Comment by European Alzheimer's Disease Consortium (EADC) investigators on the negative recommendation of the CHMP on the marketing authorization of donanemab for early Alzheimer' s disease.
Journal: The journal of prevention of Alzheimer's disease
Published: May 20, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kloppel's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile